SCYNEXIS, Inc
SCYNEXIS, Inc. is a U.S.-based biopharmaceutical company focused on developing antifungal medicines for serious and drug-resistant fungal infections. Its core platform, called fungerps, includes ibrexafungerp and the follow-on candidate SCY-247, with development, licensing, and commercialization activities centered on human health applications.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaCommercialized ibrexafungerp-based therapy marketed as BREXAFEMME for vaginal fungal infections.
SCY-247 and other pipeline compounds being developed for difficult-to-treat fungal infections.
Revenue from licensing arrangements and milestone/royalty economics tied to partnered assets.
Tuotteet
Raportoitu · osuus liikevaihdosta- License and Service93,0 %
- Products7,0 %
Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
SCYNEXIS sells into the human-health pharmaceutical market rather than to end consumers directly, so its customers include licensing partners, healthcare providers, and ultimately patients treated with antifungal therapies. Commercial demand is tied to hospitals, clinicians, and payors that need treatments for fungal infections, especially where resistance or limited options make standard therapies less effective.
Pharmaceutical companies such as GSK and other collaborators that pay for rights, milestones, and royalties.
Hospitals, specialists, and prescribers that use antifungal therapies in clinical settings.
Patients treated for vulvovaginal candidiasis, recurrent infections, or severe systemic fungal disease.
Commercial insurers and government programs that determine coverage and reimbursement.
Strategia
SCYNEXIS is focused on advancing SCY-247 through clinical development while using its partnered assets to generate non-dilutive funding. The company also seeks to expand its pipeline through in-licensing and collaboration opportunities, which can broaden its antifungal franchise without relying solely on internal discovery.
Clinical progress is the main driver of future value creation for the pipeline.
Partner economics can fund operations without relying entirely on new equity.
Additional assets can diversify scientific risk and create future commercialization options.
Maantiede
SCYNEXIS is headquartered in the United States and conducts its core research, development, and corporate activities from there. Its business also extends through licensing arrangements outside the U.S., including partnered rights in China, Russia, and other non-core markets, which makes the company dependent on international regulatory and commercial execution.
Riskit
SCYNEXIS faces the typical risks of a development-stage biopharmaceutical company: clinical failure, regulatory delay, manufacturing dependence, and reimbursement uncertainty. Its partnered model also creates concentration risk around a small number of licensing relationships, while antifungal commercialization depends on competition from generic and established therapies.
- Clinical development failure for SCY-247Vaikutus: KorkeaTodennäköisyys: Kohtalainen
The lead pipeline asset is still in development and may not show adequate safety or efficacy.
Kohdistuu: SCY-247 and future fungerp candidates
- Regulatory approval and timing riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Drug candidates require successful FDA and other regulatory reviews before commercialization.
Kohdistuu - Manufacturing and supply chain dependenceVaikutus: Korkea
The company relies on third-party CMOs and suppliers for drug product and clinical supply.
Kohdistuu: SCY-247 and licensed products
- Reimbursement and market access pressureVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Coverage decisions by payors can determine whether branded antifungals gain adoption.
Kohdistuu: BREXAFEMME and future commercial products
- Competition from generic and established antifungalsVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Existing therapies are widely available and may be cheaper or more familiar to prescribers.
Kohdistuu: Antifungal treatment market
Kirjanpito
Harkinnanvaraiset erätRevenue is driven by partner contracts and may include milestone-based or catch-up recognition.
Vaikutus: Can cause lumpy quarterly revenue and affect comparability
Clinical, preclinical, and CMC costs must be accrued based on estimates and vendor invoices.
Vaikutus: Affects reported operating loss and period timing
Equity awards are a meaningful non-cash expense for a development-stage biotech.
Vaikutus: Impacts SG&A and R&D expense trends
Shareholder and other legal claims may create disclosure or accrual requirements.
Vaikutus: Could affect liabilities and future cash outflows
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Soligenix, Inc
SNGX · Pharmaceutical Preparations
Vincerx Pharma, Inc.
Pharmaceutical Preparations
Ionis Pharmaceuticals, Inc
IONS · Pharmaceutical Preparations
Ionis Pharmaceuticals is a U.S.-based biotechnology company focused on RNA-targeted medicines, using antisense chemistry to discover and develop therapies for serious diseases.
Syndax Pharmaceuticals Inc
SNDX · Pharmaceutical Preparations
Syndax Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for hematologic malignancies and other serious diseases.
Sionna Therapeutics, Inc.
SION · Pharmaceutical Preparations
Ultragenyx Pharmaceutical Inc.
RARE · Pharmaceutical Preparations
Päivitetty: 24.9.2026